We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+23.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$10.7M
Cap. Flow
-$39.5M
Cap. Flow %
-27.17%
Top 10 Hldgs %
27.16%
Holding
316
New
137
Increased
28
Reduced
59
Closed
75

Top Buys

1
CNC icon
Centene
CNC
+$6.93M
2
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$4.78M
3
UNH icon
UnitedHealth
UNH
+$3.65M
4
CVS icon
CVS Health
CVS
+$3.53M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M

Top Sells

1
HUM icon
Humana
HUM
+$4.91M
2
EHC icon
Encompass Health
EHC
+$3.58M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$3.43M
4
AMGN icon
Amgen
AMGN
+$3.35M
5
LLY icon
Eli Lilly
LLY
+$2.53M

Sector Composition

1 Healthcare 48.9%
2 Financials 13.82%
3 Technology 6.61%
4 Consumer Discretionary 5.8%
5 Materials 5.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
176
Foghorn Therapeutics
FHTX
$305M
$55.9K 0.04%
+11,441
New +$60.7K
RLAY icon
177
Relay Therapeutics
RLAY
$4.34B
$53.7K 0.04%
10,280
– –
ABR icon
178
CALL
Arbor Realty Trust
ABR
$996M
$52.9K 0.04%
915
+612
+202% +$7.12K
VTYX
179
DELISTED
Ventyx Biosciences
VTYX
$50.7K 0.03%
+16,295
New +$43.2K
AVXL icon
180
CALL
Anavex Life Sciences
AVXL
$221M
$49.7K 0.03%
+322
New +$3.27K
ILCV icon
181
CALL
iShares Morningstar Value ETF
ILCV
$1.3B
$49.4K 0.03%
+152
New +$13.2K
BMY icon
182
CALL
Bristol-Myers Squibb
BMY
$124B
$48.1K 0.03%
+412
New +$19.2K
YSG
183
Yatsen Holding
YSG
$335M
$45.3K 0.03%
+5,000
New +$47.6K
SLNO
184
CALL
DELISTED
Soleno Therapeutics
SLNO
$44.9K 0.03%
+115
New +$8.53K
TECX
185
CALL
Tectonic Therapeutic
TECX
$615M
$42.4K 0.03%
+229
New +$4.73K
CRMD icon
186
PUT
CorMedix
CRMD
$661M
$42.1K 0.03%
+229
New +$2.77K
ARCT icon
187
PUT
Arcturus Therapeutics
ARCT
$172M
$38.6K 0.03%
+345
New +$5.54K
SMMT icon
188
CALL
Summit Therapeutics
SMMT
$10.7B
$38.1K 0.03%
175
– –
RXRX icon
189
CALL
Recursion Pharmaceuticals
RXRX
$1.56B
$37.7K 0.03%
1,606
– –
ROIV icon
190
PUT
Roivant Sciences
ROIV
$24.8B
$36.3K 0.02%
+691
New +$8.55K
SRRK icon
191
CALL
Scholar Rock
SRRK
$6.33B
$35.5K 0.02%
+229
New +$8.01K
GLD icon
192
CALL
SPDR Gold Trust
GLD
$130B
$34.4K 0.02%
+42
New +$13.4K
ATYR
193
PUT
aTyr Pharma
ATYR
$50M
$31.3K 0.02%
176
-64,245
-100% -$291K
PRTC
194
DELISTED
PureTech Health
PRTC
$31.2K 0.02%
1,685
– –
ALT icon
195
CALL
Altimmune
ALT
$558M
$28.8K 0.02%
1,064
-1,846
-63% -$7.13K
APGE icon
196
CALL
Apogee Therapeutics
APGE
$10.1B
$28.7K 0.02%
295
-67
-19% -$2.56K
VTGN icon
197
CALL
VistaGen Therapeutics
VTGN
$9.4M
$28.7K 0.02%
+231
New +$690
EDIT icon
198
CALL
Editas Medicine
EDIT
$457M
$27.7K 0.02%
+693
New +$1.93K
UWMC icon
199
CALL
UWM Holdings
UWMC
$685M
$25.3K 0.02%
+675
New +$3.54K
TSLA icon
200
CALL
Tesla
TSLA
$1.43T
$25.1K 0.02%
+10
New +$3.47K
6 7
8
9 10

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Persistent Asset Partners held 316 positions worth $145M, up 7.9% from $135M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Persistent Asset Partners withdrew a net $39.5M in Q3 2025, closing 75 positions and reducing 59 holdings. Its most notable exit was Humana, an estimated $4.91M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Persistent Asset Partners opened a new position in Centene worth $8.19M.

  • Persistent Asset Partners's largest Q3 2025 buy was Centene: 229,544 shares worth $8.19M.
  • Persistent Asset Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $3.17M increase.
  • Persistent Asset Partners's biggest Q3 2025 reduction was iShares Bitcoin Trust, cutting an estimated $3.43M.
  • Persistent Asset Partners fully exited Humana in Q3 2025, selling an estimated $4.91M.
  • Persistent Asset Partners's ten largest holdings make up 27% of its $145M portfolio in Q3 2025.
  • Persistent Asset Partners opened 137 new positions and closed 75 in Q3 2025.
  • Persistent Asset Partners's portfolio value rose 7.9% quarter-over-quarter to $145M.

Based on Persistent Asset Partners's 13F filing for Q3 2025, filed 10 Nov 2025.